Sorafenib reduces the percentage of tumo
β
Ingrid M.E. Desar; J. (Hans) F.M. Jacobs; Christina A. Hulsbergen-vandeKaa; Wim
π
Article
π
2010
π
John Wiley and Sons
π
French
β 335 KB
π 2 views
## Abstract Tyrosine kinase inhibitors (TKIs) as sorafenib are known to reduce the number of immunosuppressive regulatory T cells (Tregs) in the peripheral blood and thereby shifting the immune balance to a more stimulating setting. The effect of sorafenib on intratumoural Tregs is unclear but impo